Inter-firm collaboration in new product development in Chinese pharmaceutical companies
Inter-firm collaboration in new product development in Chinese pharmaceutical companies
复制标题
DOI：
10.1007/s10490-015-9451-y
复制
发表时间：
2015-12
影响因子：
5.4
通讯作者：
Xiaoqing Li;Yu Zheng;Catherine L. Wang
中科院分区：
文献类型：
--
作者：
Xiaoqing Li;Yu Zheng;Catherine L. Wang
高科技公司在新产品开发中越来越依赖公司间合作。虽然有越来越多的研究兴趣，探索通过交易成本经济学（TCE）的经济理由，国际金融公司的资源协同作用，通过资源为基础的企业（RBV）的观点，国际金融公司，很少有人注意到制度为基础的观点（IBV），也有重要的影响，企业的选择国际金融公司。特别是，国家体制环境如何影响国际金融公司在国家方案制定过程中的作用仍然没有得到充分研究。本研究旨在通过扩展我们对国际金融公司在企业新产品开发过程中的作用的理解，并考虑到交易、资源和制度因素，为文献做出贡献。基于对中国一家国有和一家民营制药企业的案例研究，我们的研究确定了三种主要的国际金融公司形式，它们在新产品开发的不同阶段是动态的，并取决于一系列支持企业选择不同形式国际金融公司的制度、资源和交易理由。我们的研究是第一个调查国际金融公司在新产品开发过程中的作用，汇集了IBV，RBV和TCE的观点。
High-tech firms increasingly rely on inter-firm collaboration (IFC) in new product development (NPD). While there is a growing research interest in exploring the economic rationale of IFC through the transaction cost economics (TCE) and the resource synergy of IFC through the resource-based view of the firm (RBV), little attention has been given to the institution-based view (IBV) that also has important implications for firms’ choice of IFC. In particular, how national institutional environment affects IFC in the NPD process remains under-researched. This study aims to contribute to the literature by extending our understanding of the role of IFC in firms’ NPD process, taking into account transactional, resource, and institutional factors. Based on a case study of two firms: a state-owned and a private pharmaceutical firm in China, our research identifies three key forms of IFC, which are dynamic at different stages of NPD and contingent upon an array of institutional, resource, and transactional rationales underpinning firms’ choice of different forms of IFC. Our study is the first one that investigates the role of IFC in the NPD process bringing together the IBV, RBV, and TCE perspectives.